Search results for "Clero"

showing 10 items of 2052 documents

Postprandial Changes in Chemokines Related to Early Atherosclerotic Processes in Familial Hypercholesterolemic Subjects: A Preliminary Study.

2015

Familial hypercholesterolemia (FH) is associated with higher levels of inflammatory mediators such as chemokines, which contribute to an increased risk of premature atherosclerosis in these patients. We studied the response of chemokines related to early atherosclerotic processes during an oral unsaturated fat load test (OFLT) in patients with heterozygous FH and compared this response to normolipidemic and normoglycemic subjects.Blood samples were taken from 12 FH patients and 20 healthy controls with a similar age, gender distribution, and body mass index. Plasma chemokine levels were determined in both groups in a fasting state and at 2, 4, 6, and 8 h after an OFLT using human cytokine m…

0301 basic medicineAdultMaleChemokinemedicine.medical_specialtyAdolescentmedicine.medical_treatmentFamilial hypercholesterolemia030204 cardiovascular system & hematologyBody Mass IndexHyperlipoproteinemia Type II03 medical and health scienceschemistry.chemical_compoundYoung Adult0302 clinical medicineDietary Fats UnsaturatedInternal medicineMedicineHumansHyperlipoproteinemia Type IIAgedbiologybusiness.industryUnsaturated fatCase-control studyGeneral MedicineFastingMiddle Agedmedicine.diseaseAtherosclerosisPostprandial PeriodHealthy Volunteers030104 developmental biologyEndocrinologyCytokinePostprandialchemistryCase-Control Studiesbiology.proteinFemaleChemokinesbusinessBody mass indexArchives of medical research
researchProduct

Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS.

2019

ObjectiveWe explored the incremental value of adding multiple disease activity biomarkers in CSF and serum for distinguishing MRI-based benign from aggressive MS in early disease course.MethodsNinety-three patients diagnosed with clinically isolated syndrome (CIS) or early MS were divided into 3 nonoverlapping severity groups defined by objective MRI criteria. Ninety-seven patients with noninflammatory neurologic disorders and 48 patients with other inflammatory neurologic diseases served as controls. Leukocyte subsets in the CSF were analyzed by flow cytometry. CSF neurofilament light chain (NfL) and chitinase-3-like protein 1 (CHI3L1) levels were measured by ELISA. Serum NfL levels were e…

0301 basic medicineAdultMalePathologymedicine.medical_specialtyAdolescent41medicine.medical_treatmentCHI3L1ArticleFlow cytometryCohort Studies03 medical and health sciencesYoung Adult0302 clinical medicineText miningMultiple Sclerosis Relapsing-RemittingNeurofilament ProteinsMedicineHumansB cellAgedCD20Aged 80 and overB-LymphocytesClinically isolated syndromebiologymedicine.diagnostic_testbusiness.industryMultiple sclerosisImmunotherapyMiddle Agedmedicine.diseaseMagnetic Resonance ImagingAxons030104 developmental biologymedicine.anatomical_structureCross-Sectional StudiesNeurologybiology.proteinDisease ProgressionFemaleNeurology (clinical)business030217 neurology & neurosurgeryDemyelinating DiseasesNeurology(R) neuroimmunologyneuroinflammation
researchProduct

Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and De…

2016

Objective.Microvascular damage is pivotal in the pathogenesis of systemic sclerosis (SSc), preceding fibrosis, and whose trigger is not still fully understood. Perivascular progenitor cells, with profibrotic activity and function, are identified by the expression of the isoform 12 of ADAM (ADAM12) and this molecule may be upregulated by transforming growth factor-β (TGF-β). The goal of this work was to evaluate whether pericytes in the skin of patients with diffuse cutaneous SSc (dcSSc) expressed ADAM12, suggesting their potential contribution to the fibrotic process, and whether TGF-β might modulate this molecule.Methods.After ethical approval, mesenchymal stem cells (MSC) and fibroblasts …

0301 basic medicineAdultMalePathologymedicine.medical_specialtyImmunologyADAM12 Protein03 medical and health sciencesYoung AdultRheumatologyFibrosisTransforming Growth Factor betamedicineImmunology and AllergyHumansProgenitor cellMyofibroblastsSkinintegumentary systembusiness.industryMedicine (all)FIBROSIS; PERICYTE; SYSTEMIC SCLEROSIS; Rheumatology; Immunology; Immunology and AllergyMesenchymal stem cellTransdifferentiationMesenchymal Stem CellsMiddle Agedmedicine.diseaseFibrosisActinsUp-RegulationSettore MED/16 - Reumatologia030104 developmental biologymedicine.anatomical_structurePERICYTEFIBROSIS; PERICYTE; SYSTEMIC SCLEROSIS; Immunology and Allergy; Rheumatology; Immunology; Medicine (all)SYSTEMIC SCLEROSISCell TransdifferentiationScleroderma DiffuseFemalePericyteBone marrowbusinessPericytesMyofibroblastTransforming growth factorThe Journal of rheumatology
researchProduct

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.

2021

ObjectiveTo evaluate the clinical consequences of extended interval dosing (EID) of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) during the coronavirus disease 2019 (COVID-19) pandemic.MethodsIn our retrospective, multicenter cohort study, we compared patients with RRMS on EID (defined as ≥4-week delay of dose interval) with a control group on standard interval dosing (SID) at the same period (January to December 2020).ResultsThree hundred eighteen patients with RRMS were longitudinally evaluated in 5 German centers. One hundred sixteen patients received ocrelizumab on EID (median delay [interquartile range 8.68 [5.09–13.07] weeks). Three months after the last ocrelizumab in…

0301 basic medicineAdultMalemedicine.medical_specialty41Antigens CD19MedizinLogistic regressionAntibodies Monoclonal HumanizedArticle2303 medical and health sciencesDisability Evaluation0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInterquartile rangeInternal medicinemedicineHumansDosingLymphocyte CountPandemicsRetrospective Studies360B-Lymphocytes120business.industryMultiple sclerosisCOVID-19Retrospective cohort studyMiddle Agedmedicine.diseaseMagnetic Resonance Imaging030104 developmental biologyTreatment OutcomeNeurologyCohortOcrelizumabFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugCohort studyNeurology(R) neuroimmunologyneuroinflammation
researchProduct

Lacosamide in patients with temporal lobe epilepsy: An observational multicentric open-label study.

2016

Abstract Purpose The aim of this study was to evaluate the efficacy and tolerability of lacosamide (LCM) both as add-on therapy and monotherapy in patients with temporal lobe epilepsy (TLE) based on an observational, prospective, multicenter study. Methods We enrolled 100 patients (mean age: 43.4 ± 12.53 years, 57 females) with nonlesional TLE and TLE with hippocampal sclerosis (HS) that did not respond to the first drug and who were referred to epilepsy centers of the University of Catanzaro, University of Palermo, IRCSS Neuromed of Pozzilli, and Otto-von-Guericke University of Magdeburg. In this open-label, multicenter trial, patients were initiated on oral LCM as add-on therapy to first …

0301 basic medicineAdultMalemedicine.medical_specialtyLacosamideCohort Studies03 medical and health sciencesBehavioral NeuroscienceEpilepsyYoung Adult0302 clinical medicineLacosamideMulticenter trialInternal medicineAcetamidesMedicineHumansProspective StudiesAdverse effectProspective cohort studyHippocampal sclerosisbusiness.industryMiddle Agedmedicine.diseaseMagnetic Resonance Imaging030104 developmental biologyNeurologyTolerabilityEpilepsy Temporal LobeAnesthesiaConcomitantAnticonvulsantsDrug Therapy CombinationFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugFollow-Up StudiesEpilepsybehavior : EB
researchProduct

Vitamin D receptor polymorphisms and 25-hydroxyvitamin D in a group of Sicilian multiple sclerosis patients

2016

Multiple sclerosis (MS) is an auto-immune disease whose etiology remains controversial. Both genetic and environmental factors are thought to be involved in the risk of developing the disease. The purpose of our study was to assess the association of Vitamin D receptor (VDR) polymorphisms with MS and to investigate the interaction of these polymorphisms with vitamin D levels. A total of 179 Sicilian subjects, including 104 MS patients and 75 healthy controls, were studied. The most common VDR polymorphisms (Fok-I, Bsm-I, Taq-I and Apa-I) were genotyped by polymerase chain reaction (PCR) followed by restriction fragment length polymorphism (RFLP) analyses in both groups and serum 25-hydroxyv…

0301 basic medicineAdultMalemedicine.medical_specialtyMultiple SclerosisGenotypeVDR polymorphismsDermatologyCalcitriol receptor25(OH)D; Multiple sclerosis; VDR polymorphisms; Vitamin D; Adult; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Multiple Sclerosis; Receptors Calcitriol; Sicily; Vitamin D; Polymorphism Restriction Fragment Length03 medical and health sciences0302 clinical medicineGene FrequencyCalcitriolInternal medicineGenotypeReceptorsmedicineGenetic predispositionVitamin D and neurologyHumansMultiple sclerosiAlleleVitamin DPolymorphismAllele frequencySicilyVDR25(OH)Dbusiness.industryMultiple sclerosisGeneral MedicineMiddle Agedmedicine.diseaseVitamin D 25(OH)DPsychiatry and Mental healthSettore BIO/12 - Biochimica Clinica E Biologia Molecolare Clinica030104 developmental biologyEndocrinologyRestriction Fragment LengthImmunologyReceptors CalcitriolSettore MED/26 - NeurologiaFemaleNeurology (clinical)Restriction fragment length polymorphismbusiness030217 neurology & neurosurgeryPolymorphism Restriction Fragment Length
researchProduct

CYP27A1, CYP24A1, and RXR-α Polymorphisms, Vitamin D, and Multiple Sclerosis: a Pilot Study.

2018

Multiple sclerosis (MS) is a neurodegenerative autoimmune disease resulting from a complex interaction of genetic and environmental factors. Hypovitaminosis D seems to contribute to MS susceptibility as both an environmental and a genetic risk factor. The aim of our study was to investigate the association of SNPs in CYP27A1, CYP24A1, and RXR- α genes, vitamin D status, and MS risk. We performed a nested case-control study on patients with multiple sclerosis and healthy controls. Serum 25(OH)D3 levels and genotyping of CYP27A1, CYP24A1, and RXR-α -SNPs were investigated both in MS patients and in healthy controls. Serum 25(OH)D3 levels were measured by a high-performance liquid chromatograp…

0301 basic medicineAdultMalemedicine.medical_specialtyMultiple SclerosisRXRSingle-nucleotide polymorphismPilot ProjectsPolymorphism Single Nucleotide03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineInternal medicineGenotypemedicineVitamin D and neurologyHumansVitamin DAlleleVitamin D3 24-HydroxylaseGenotypingAutoimmune disease25-Hydroxyvitamin D 2Retinoid X Receptor alphabusiness.industryMultiple sclerosisGeneral MedicineMiddle Agedmedicine.diseaseMinor allele frequencyCYP24A1030104 developmental biologyEndocrinologyCase-Control StudiesCYP27A1Cholestanetriol 26-MonooxygenaseFemalebusiness030217 neurology & neurosurgeryJournal of molecular neuroscience : MN
researchProduct

Clinical implications of serum neurofilament in newly diagnosed MS patients: a longitudinal multicentre cohort study

2020

Abstract Background We aim to evaluate serum neurofilament light chain (sNfL), indicating neuroaxonal damage, as a biomarker at diagnosis in a large cohort of early multiple sclerosis (MS) patients. Methods In a multicentre prospective longitudinal observational cohort, patients with newly diagnosed relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS) were recruited between August 2010 and November 2015 in 22 centers. Clinical parameters, MRI, and sNfL levels (measured by single molecule array) were assessed at baseline and up to four-year follow-up. Findings Of 814 patients, 54.7% (445) were diagnosed with RRMS and 45.3% (369) with CIS when applying 2010 McDonald criteria (R…

0301 basic medicineAdultMalemedicine.medical_specialtyResearch paperClinical Decision-MakingIntermediate Filamentslcsh:Medicine610 Medicine & healthNewly diagnosedGeneral Biochemistry Genetics and Molecular BiologyMultiple sclerosis03 medical and health sciences0302 clinical medicineAtrophyMultiple Sclerosis Relapsing-RemittingNeurofilament ProteinsInternal medicineGermanymedicineHumansLongitudinal StudiesProspective Studiesddc:610610 Medicine & healthNeurofilament light chainlcsh:R5-920Clinically isolated syndromebusiness.industryMultiple sclerosislcsh:RMcDonald criteriaGeneral MedicineBiomarkermedicine.diseasesNfL030104 developmental biology030220 oncology & carcinogenesisCohortDisease ProgressionCommentaryBiomarker (medicine)Femalelcsh:Medicine (General)businessPredictionFunction and Dysfunction of the Nervous SystemBiomarkersCohort study
researchProduct

Role of Haptoglobin as a Marker of Muscular Improvement in Patients with Multiple Sclerosis after Administration of Epigallocatechin Gallate and Incr…

2021

Here, we report on the role of haptoglobin (Hp), whose expression depends on the synthesis of interleukin 6 (IL-6), related to the pathogenesis of multiple sclerosis (MS), as a possible marker of muscle improvement achieved after treatment with the polyphenol epigallocatechin gallate (EGCG) and an increase in the ketone body beta-hydroxybutyrate (BHB) in the blood. After 4 months of intervention with 27 MS patients, we observed that Hp does not significantly increase, alongside a significant decrease in IL-6 and a significant increase in muscle percentage. At the same time, Hp synthesis is considerably and positively correlated with IL-6 both before and after treatment

0301 basic medicineAdultMalemedicine.medical_specialtyepigallocatechin gallateMultiple Sclerosisbeta-hydroxybutyratemuscleinterleukin 6Pilot ProjectsEpigallocatechin gallateMicrobiologyBiochemistryCatechinArticlePathogenesis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBeta hydroxybutyrateInternal medicinemedicineHumansIn patientInterleukin 6Muscle SkeletalMolecular Biologybiology3-Hydroxybutyric AcidHaptoglobinsbusiness.industryInterleukin-6Multiple sclerosisHaptoglobinfood and beveragesMiddle Agedmedicine.diseaseQR1-502haptoglobin030104 developmental biologyEndocrinologychemistrybiology.proteinKetone bodiesFemalebusiness030217 neurology & neurosurgeryBiomarkersBiomolecules
researchProduct

The function of matrix metalloproteinase-9 (MMP-9) and its tissue inhibitor (TIMP-1) in several clinical conditions: Results and analysis of our surv…

2021

The goal of this research was to evaluate the plasma concentration of MMP-9 and its tissue inhibitor (TIMP-1) in different clinical conditions. It included several groups of subjects: 31 overweight subjects; 91 obese adults divided into two subgroups according to the BMI value (BMI 30–35 Kg/m2 and BMI > 35 Kg/m2); 90 subjects with metabolic syndrome (MS) divided into two subgroups (with and without diabetes mellitus); 100 subjects with preclinical carotid atherosclerosis (PCA) divided according to the number of cardiovascular risk factors and to the insulin resistance degree; 48 subjects with obstructive sleep apnoea syndrome (OSAS) divided according to the apnoea/hypopnea index (AHI); 2…

0301 basic medicineAdultmedicine.medical_specialtyPhysiologymedicine.medical_treatment030204 cardiovascular system & hematologyOverweightAdult CKD Humans metabolic syndrome Matrix Metalloproteinase 9 Metabolic Syndrome MMP-9 Obesity OSAS preclinical carotid atherosclerosis Sleep Apnea Obstructive TIMP-1 Tissue Inhibitor of Metalloproteinase-103 medical and health sciences0302 clinical medicineInsulin resistancePhysiology (medical)Diabetes mellitusInternal medicinemedicineHumansObesityDialysisMetabolic SyndromeSleep Apnea ObstructiveTissue Inhibitor of Metalloproteinase-1business.industryHematologymedicine.diseaseObesity030104 developmental biologyMatrix Metalloproteinase 9medicine.symptomMetabolic syndromeCardiology and Cardiovascular MedicinebusinessHypopneaKidney diseaseClinical hemorheology and microcirculation
researchProduct